Venture Capital Pain Point: The “Operational Blind Spot”.

The Problem:

You can assess the science and the market, but can you be sure the clinical plan is actually executable? A flawed protocol, an unrealistic budget, or a poor CRO selection can destroy your investment post-close.

Our Solution:

Clinical & Operational Due-Diligence Sprint

• The Fix: We act as your operational lens. In 4 weeks, we pressure-test the clinical development plan, vendor strategy, and financial model of a target company or asset.
• VC Outcome: You get a clear, data-driven “Go/No-Go” signal on operational viability before you sign the term sheet, protecting your capital from costly execution risks.

Price:

Pricing Rationale: Considering a VC is potentially deploying a $5M-$15M in a Series A  round of investment, this works out to less than 1% of the capital at risk for a potential due diligence assignment.

Tiered pricing structure:

• Tier 1 (from $40,000 USD): Small molecule, established mechanism of action (MOA), straightforward design for Phase 1/2 trials.
• Tier 2 (from $60,000 USD): Biologic, novel target, more complex trial design e.g. Adaptive Clinical Trial Designs like Basket Designs and Platform Designs
• Tier 3 (from $75,000 USD): Advanced modality (cell/gene therapy), complex manufacturing/CMC challenges, global trial.